New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:32 EDTORMPOramed granted 3rd patient in Australia for oral administration of exenatide
Oramed announced that IP Australia, the Australian government's patent office, has issued the company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.Oramed has planned a comprehensive clinical program for ORMD-0901, with the goal of seeking approval in the U.S. and other territories. IND-enabling toxicity studies are scheduled to begin later this year in the U.S. and a Phase 1b study outside of the U.S. is also planned for 2014.
News For ORMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
10:46 EDTORMPOramed management to meet with Roth Capital
Meeting to be held in New York on January 26 hosted by Roth Capital.
January 16, 2015
08:30 EDTORMPOramed granted patent in Israel for oral administration of GLP-1
Oramed announced that the Israel Patent Office has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Exenatide."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use